Moderna, Pfizer and COVID-19
1d
Investor's Business Daily on MSNWhy Moderna Stock Has Surged 20% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
The police and fire-rescue departments partnered with the town manager’s office to guide the town’s COVID-19 response.
Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results